特朗普签署行政令：加快迷幻药物在精神健康领域的审查与应用Trump Signs Executive Order to Fast-Track Psychedelic Drugs for Mental Health Treatment
美国总统唐纳德·特朗普于2026年4月18日周六在白宫椭圆形办公室签署了一项行政命令，正式指示其政府加快对特定迷幻药物的审查。该命令的核心目标是放宽对伊博格碱（ibogaine）和赛洛西宾（psilocybin）等物质的联邦限制，以便将其用于治疗抑郁症、焦虑症和创伤后应激障碍（PTSD）等严重的精神健康疾病。特朗普在签署现场表示，这项举措旨在确保那些正遭受“衰弱性症状”折磨的民众能够获得新的治疗机会，从而改善生活质量并重获幸福。此次行动不仅涉及政策层面的加速审查，还包括了5000万美元的资金投入，用于支持相关的医疗研究和临床评估。
President Donald Trump signed an executive order in the Oval Office on Saturday, April 18, 2026, directing his administration to expedite the review of certain psychedelic drugs for medical use. The order specifically targets substances such as ibogaine and psilocybin, aiming to ease federal restrictions that have long hindered their application in treating mental health conditions like depression, anxiety, and post-traumatic stress disorder (PTSD). Speaking during the signing ceremony, Trump emphasized that the directive is intended to ensure individuals suffering from debilitating symptoms have a chance to reclaim their lives. In addition to streamlining the regulatory process, the administration is allocating $50 million to facilitate research into the therapeutic potential of these controversial substances.
这一政策转变发生在美国精神健康危机日益严重的背景下，尤其是退伍军人群体对新型疗法的需求不断增加。尽管伊博格碱等药物目前仍被列入联邦政府最严格的禁药名单（即高风险、无公认医疗用途的类别），但特朗普政府正试图通过行政手段打破这一僵局。此举被视为对传统精神病学疗法的一种补充，同时也反映了公众和部分政治力量对迷幻药物医疗价值认知的显著变化。通过将这些药物从单纯的管控对象转变为潜在的医疗资源，白宫正试图在公共卫生政策上开辟一条极具争议但可能产生深远影响的新路径。
This policy shift comes amid a growing mental health crisis in the United States, with increasing demand for innovative therapies, particularly among combat veterans. Although substances like ibogaine remain classified under the federal government's most restrictive category for illegal, high-risk drugs, the Trump administration is taking decisive steps to lower barriers to access for research purposes. The move is seen as a supplement to traditional psychiatric treatments and reflects a significant shift in how the medical potential of psychedelics is perceived by both the public and policymakers. By transitioning these substances from strictly controlled contraband to potential medical assets, the White House is charting a controversial but potentially transformative course in public health policy.
01伊博格碱与退伍军人的推动作用Ibogaine and the Influence of Combat Veterans
在受此次行政令影响的药物中，伊博格碱因其极高的争议性和潜在的成瘾治疗效果而备受关注。这种物质提取自西非的一种植物，近年来得到了作战退伍军人群体的广泛拥护。许多退伍军人报告称，伊博格碱在治疗与战争相关的创伤和药物依赖方面具有显著效果，这促使相关组织不断向政府施压，要求放宽研究限制。特朗普在签署仪式上也特别提到了这些药物对改善患者生活、让他们“过上更快乐生活”的重要性。
Among the drugs highlighted in the executive order, ibogaine stands out due to its controversial nature and its potential for treating addiction. Derived from a plant native to West Africa, the substance has recently been embraced by combat veterans who credit it with helping them overcome war-related trauma and substance abuse. This grassroots support from the veteran community has been a primary driver in pressuring the government to relax research restrictions. During the signing, Trump noted that the order would help people reclaim their lives, emphasizing the human impact of these potential treatments.
“今天的命令将确保那些遭受衰弱症状折磨的人们终于有机会夺回他们的生活，并过上更幸福的生活。”
"Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life."
唐纳德·特朗普，美国总统Donald Trump, President of the United States
02乔·罗根的出席与公众倡导Joe Rogan's Presence and Public Advocacy
此次签署仪式的一个显著特点是著名播客主持人乔·罗根的出席。罗根被认为是美国最具影响力的媒体人之一，他长期以来一直是伊博格碱和其他迷幻药物医疗化的主要倡导者。他在其播客节目中多次讨论这些物质在治疗心理疾病方面的潜力，并呼吁政府改变现有的严厉管控政策。罗根出现在椭圆形办公室，不仅凸显了该议题在流行文化中的热度，也反映了特朗普政府愿意采纳非传统意见领袖建议的姿态。
A notable aspect of the signing ceremony was the presence of influential podcaster Joe Rogan. Rogan, who commands a massive audience, has been a leading proponent of the medical use of ibogaine and other psychedelics. He has frequently used his platform to discuss the potential benefits of these substances for mental health and has called for a reevaluation of current federal restrictions. His appearance in the Oval Office underscores the intersection of popular culture and public policy, signaling the administration's willingness to engage with non-traditional advocates on high-stakes health issues.
03法律现状与监管挑战Legal Status and Regulatory Challenges
尽管行政命令要求加快审查，但迷幻药物在法律层面仍面临巨大障碍。目前，伊博格碱和赛洛西宾仍被列为联邦政府最严格管控的类别，这意味着它们被认为具有高滥用风险且缺乏公认的医疗价值。特朗普的命令旨在通过指示FDA等机构优化流程，来缓解这些限制对科研的束缚。下表概述了此次行政令涉及的主要药物及其当前状态：
Despite the executive order's push for speed, significant legal hurdles remain for psychedelic drugs. Currently, substances like ibogaine and psilocybin are classified under the federal government's most restrictive category, indicating a high potential for abuse and no accepted medical use. Trump's order seeks to mitigate these barriers by directing agencies like the FDA to streamline their processes. The following table outlines the key substances mentioned and their current regulatory context:
| 药物名称 | 当前法律地位 | 主要针对病症 |
|---|---|---|
| 伊博格碱 (Ibogaine) | 联邦最严格管控药物 | 成瘾治疗、PTSD |
| 赛洛西宾 (Psilocybin) | 联邦最严格管控药物 | 抑郁症、焦虑症 |
| Drug Name | Current Legal Status | Primary Target Conditions |
|---|---|---|
| Ibogaine | Most restrictive federal category | Addiction, PTSD |
| Psilocybin | Most restrictive federal category | Depression, Anxiety |
特朗普政府公共卫生领导层调整背景Trump Administration Public Health Leadership Context
梳理特朗普政府在签署迷幻药物行政令期间，对关键公共卫生机构领导层的重组过程。
Outlines the restructuring of key public health leadership during the period of the psychedelics executive order.
特朗普总统提名曾任副卫生总监的埃里卡·施瓦茨担任美国疾控中心（CDC）主任，旨在结束该机构长达数月的领导层动荡。
President Trump nominated former Deputy Surgeon General Erica Schwartz to lead the CDC, aiming to stabilize the agency after months of leadership turnover.
随着CDC新主任的提名，特朗普政府开始整合卫生机构资源，为后续通过行政手段推动特定医疗领域（如迷幻药物审查）的改革铺平道路。
With the new CDC nomination, the Trump administration began aligning health agency resources, setting the stage for executive-led reforms in specific medical sectors like psychedelic drug reviews.
特朗普正式签署行政命令，拨款5000万美元并指示联邦机构加快对伊博格碱和赛洛西宾等药物的审查，标志着其医疗监管改革进入新阶段。
Trump officially signed the executive order allocating $50 million to expedite reviews of ibogaine and psilocybin, marking a new phase in his medical regulatory reform agenda.
08多源对比Source Comparison
同一事件下，不同媒体的标题与原文节选往往呈现不同关注点。这里汇总最核心的几条报道，方便快速交叉比对。
Coverage of the same event often emphasizes different angles. This view puts the most relevant reports side by side for quick cross-checking.
Trump expedites review of psychedelics to treat mental health disorders President endorses psilocybin and ibogaine: "Can...
United States President Donald Trump has signed an executive order to speed up the review of a handful of psychedelic dr...
WASHINGTON (AP) — President Donald Trump on Saturday directed his administration to speed up reviews of certain psychede...